Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production

Ruth J. Pepper(Hammersmith Hospital), Margarete A. Fabre(University College London), Carlos Pavésio(University College London), G. Gaskin(Imperial College London), Rachel Jones(Hammersmith Hospital), David Jayne(Imperial College London), Charles D. Pusey(Hammersmith Hospital), Alan D. Salama(Addenbrooke's Hospital)
Lara D. Veeken
April 25, 2008
10.1093/rheumatology/ken175
Cited by 148Open Access
Full Text

Abstract

required combination chemotherapy and an association with EBV was not identified.

Related Papers

No related papers found

Powered by citation graph analysis